Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
79 hedge funds and large institutions have $74.2M invested in Surface Oncology, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 30 reducing their positions, and 10 closing their positions.
980% more call options, than puts
Call options by funds: $108K | Put options by funds: $10K
126% more capital invested
Capital invested by funds: $32.9M → $74.2M (+$41.3M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
0% more funds holding
Funds holding: 79 → 79 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
47% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$424K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$189K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$154K |
| 4 |
Jane Street
New York
|
+$130K |
| 5 |
E
Ergoteles
New York
|
+$51.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$769K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$462K |
| 3 |
BlackRock
New York
|
-$344K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$313K |
| 5 |
Barclays
London,
United Kingdom
|
-$306K |
SURF Hedge Fund Activity: Q4 2022 in Review
79 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2022, worth a combined $74.2M — up 126% from $32.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SURF positions and 10 closed out — a net gain of 2 holders — while 16 added to existing stakes and 30 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $424K. The largest seller was Citadel Advisors, cutting an estimated $769K.
- 79 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $74.2M of Surface Oncology, Inc. Common Stock stock for Q4 2022, up 126% quarter-over-quarter.
- 12 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of +2 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q4 2022 was Tang Capital Management, an estimated $424K added.
- The largest Surface Oncology, Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $769K sold.
Based on aggregated 13F filings for Q4 2022.